Episode 92: The decade in breakthroughs, the year in bad CEOs, and the viruses that cure disease
Which drug defined the decade? Who's the worst CEO in biopharma? And how does gene therapy actually work?
Dec 19, 2019•25 min
The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Episode 91: CAR-T's future, an alarming cancer trend & Chris Garabedian on Sarepta's FDA legacy
Has CAR-T lost its luster? Why is colorectal cancer on the rise? And did the FDA forever change in 2016?
Dec 12, 2019•25 min
Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep
How do you know if a "positive" study is positive? And how did one-eyed sheep lead to a drug for certain cancers?
Dec 05, 2019•25 min
Episode 89: Warren's awkward home front, a dwarfism drug, and the sound of STAT Summit
Can Sen. Elizabeth Warren ever go home again? Is it ethical to make little people taller? And when will AI come up with a new drug?
Nov 22, 2019•25 min
Episode 88: Dr. David Sable on an alarming genetic test & Jorge Conde on the perils of bio-Twitter
Do you trust Google with your health data? Is "Gattaca" an outdated reference? And what's it like to get dunked on?
Nov 14, 2019•26 min
Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday
Why hope for China's new Alzheimer's drug turned into skepticism ? Is three a crowd in CAR-T? And what's a Bionomy?
Nov 07, 2019•20 min
Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation'
When should a drug be pulled from shelves? How do you pronounce "HLTH?" And how does Ann Coulter decide what to tweet?
Oct 31, 2019•28 min
Episode 85: Every angle on Biogen's shocking Alzheimer's news
What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that aducanumab, its once-discarded treatment for Alzheimer's disease, is getting a second life.
Oct 24, 2019•28 min
Episode 84: CRISPR with Netflix filmmakers, Pharma's future in China & where VC dollars come from
Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog?
Oct 17, 2019•26 min
Episode 83: How biotech VC works w/ health care journalist Maggie Fox, Vioxx and synthetic biology
STAT's Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology industry is growing up and getting corporate. Finally, health care journalist Maggie Fox dials in to explain her deep dive on venture capital in biotech.
Oct 10, 2019•24 min
Episode 82: Drug shortages with Dr. Ben Davies, congressional paralysis & biotech's foul mood
Does impeachment have a pharma angle? Who's to blame for drug shortages? And why is Wall Street down on biotech?
Oct 03, 2019•23 min
Episode 81: Vaping upheaval, DNA test dynamics, & the future of genome editing
What do we talk about when we talk about "vape"? Are there limits to business of DNA testing? And how hard is it to get yourself CRISPR'd? STAT's Megan Thielking joins the gang to break down a major week of news in the world of vaping and STAT's Sharon Begley relates the story of a desperate patient seeking off-the-books genome editing and its implications for the future of medical research.
Sep 26, 2019•26 min
Episode 80: Unicorn growth spurts, Amgen's future, & mice on Twitter
Who puts horns on unicorns? How do graying drug companies find green ideas? And what would mice tweet?
Sep 19, 2019•29 min
Episode 79: Pelosi's drug pricing plan, Moderna's mRNA drug factories, and a DIY disease cure
House Speaker Nancy Pelosi’s drug pricing plan is aggressive, but is it viable? Can Moderna turn cells into tiny drug-making factories? What’s it like to cure your own rare disease?
Sep 12, 2019•20 min
Episode 78: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue
What separates good drug companies from mediocre ones? Have biohackers sold out? And who's going to run the FDA?
Sep 05, 2019•24 min
Episode 77: Purdue, J&J, and a week of big opioid crisis news
What does Dr. Richard Sackler sound like? When is $500 million a small amount of money? And what will come of the drug companies at the heart of the opioid crisis?
Aug 29, 2019•18 min
Episode 76: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech
How should you talk to friends about rejection? Can Facebook actually improve the lives of children? And how's biotech doing in China?
Aug 22, 2019•23 min
Episode 75: The serious side of spit kits, how BiTEs leave a mark, & Sarepta's sluggish study
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work?
Aug 15, 2019•30 min
Episode 74: Novartis and the no good, very bad week
Why did Novartis (NVS) keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?
Aug 08, 2019•20 min
Episode 73: Canadian pills, corporate jets, & racists with spit kits
Will Canada run out of drugs? Should you ever read your partner's diary? And what does Pepe the Frog know about genomics?
Aug 01, 2019•24 min
Episode 72: Vertex's regime change, the return of Ebola, & the rise of digital health
What makes an epidemic newsworthy? Can biotech succession succeed? And what's so novel about digital health?
Jul 25, 2019•27 min
Episode 71: Elon Musk's monkey cyborg, Gilead's shifting future, & an app for anxiety
Can apps treat anxiety? Is Gilead Sciences back on track? And are we all just brains in a vat?
Jul 18, 2019•26 min
Episode 70: A whirlwind week in Washington, Sean Parker's mansion, & remembering a voice in biotech
Is drug pricing too complex for the Trump administration? Would you recognize Tom Hanks at a party? And what does it mean when famous executives quit?
Jul 11, 2019•30 min
Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing
Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?
Jun 27, 2019•26 min
Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life
Is desire a matter of medicine? Can you convict on genealogy? And what do you get the alleged bride who has it all?
Jun 20, 2019•27 min
Episode 67: Biohacking meets bureaucracy, and the latest twist in CRISPR world
Is biohacking a crime? Who came up with the latest CRISPR trick? And did Rage Against the Machine sell out?
Jun 13, 2019•25 min
Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party
Who won ASCO? Is pharma sandbagging its blockbusters? And what do gladiators have to do with biotech?
Jun 06, 2019•27 min
Episode 65: A special episode from the halls of the ASCO meeting
What can be done to improve HPV vaccination rates in the U.S.? How does the genetic signature of a tumor lead to an effective cancer drug? What’s it like being a doctor and a cancer patient?
Jun 04, 2019•29 min
Episode 64: Feuding professors, failing businesses, and journalism 101
Who's guilty of "clickbait"? Are spit tubes a bad business? And why are academics emulating Pusha T?
May 30, 2019•24 min
Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer
What should you watch for at the year's biggest cancer conference? Why are people having 23andMe-induced identity crises? And what's it like to be at once a journalist and a cancer patient?
May 23, 2019•32 min
Hosted on Megaphone by Spotify
For the best experience, listen in Metacast app for iOS or Android